Value Adjusted for Debt and Cash: carismatx.com (CARM)
The market valuation chart for Carisma Therapeutics (CARM) on the GURU.Markets platform is currently at . The current business relies on early-stage trials of drugs targeting solid tumors, where capacity expansion is currently driving higher costs. The project is based on a patent-protected macrophage modification system that ensures stable demand. This innovative approach allows cells to penetrate deep into lung and breast tumors.
Carisma Therapeutics Inc. (CARM) - metric breakdowns and financial figures
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book capitalization information:
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Carisma Therapeutics|CARM - Long-Term Debt to Capital|Short-Term Debt to Capital Carisma Therapeutics Inc|CARM - Company Debts|Debt to Net Assets Ratio Carisma Therapeutics|CARM - Company Long-Term Debt|Company Current Liabilities Carisma Therapeutics|Quick Ratio carismatx.com
- earnings and multiples data:
Analysis of all company metrics:Carisma Therapeutics
The enterprise value of Carisma Therapeutics (CARM) reflects the total capital required for a complete buyout of the business. By analyzing market value alongside liquidity and liabilities, we sum the market capitalization and net debt. This metric eliminates speculative noise to determine the asset's real price. For a biotechnology innovator in macrophage therapy, this is a key indicator for valuing intellectual property. Investors must avoid buying at cycle peaks to prevent prolonged drawdowns.
Competitors of Carisma Therapeutics (CARM)
Enterprise Value argenx N.V. ARGX|BNTX - Total Company Value|Value Adjusted for Debt and Cash ABVX (Abivax Pharma)|ADMA Biologics (ADMA) - Total Company Value|Real Price to Acquire Entire Company protagonist-inc.com|Total Company Value Immunovant|Kiniksa Pharmaceuticals, Ltd. - Full Business Value|Enterprise Value GRFS|ADPT (Adaptive Biotechnologies Inc.) - Value Adjusted for Debt and Cash|Enterprise Value CLDX (Celldex Therapeutics)|Enterprise Value auriniapharma.com AUPH|BCRX - Total Company Value|Value Adjusted for Debt and Cash VERA (Vera Therapeutics Inc)|Dianthus Pharma (DNTH) - Total Company Value|Real Price to Acquire Entire Company Pharvaris Pharma|ABCL (AbCellera Biologics Inc) - Enterprise Value|Enterprise Value tourmalinebio.com|Real Price to Acquire Entire Company PGEN (Precigen)|PHAR (Pharming Group NV) - Value Adjusted for Debt and Cash|Enterprise Value NKTR (Nektar)|Company Buyout Price Upstream Pharma (UPB)|ZBIO - Total Company Value|immunome.com (IMNM) - Real Price to Acquire Entire Company|Gossamer Bio (GOSS) - Total Company Value|Real Price to Acquire Entire Company KalVista Pharma|Real Price to Acquire Entire Company SEPN|Enterprise Value Pieris Corp|Total Company Value Savara Inc. (SVRA)|rigel.com - Business Value|Enterprise Value ANAB (AnaptysBio)|Astria Therapeutics Inc (ATXS) - Total Enterprise Value|enGene Bio - Enterprise Value|RAPT Therapeutics Inc. (RAPT) - Real Price to Acquire Entire Company|JBIO: Enterprise Value|aclaristx.com (ACRS) - Enterprise Value|Total Company Value Kyverna Therapeutics, Inc.|TLSA: Value Adjusted for Debt and Cash|Enterprise Value CABA|Company Buyout Price Ventyx Biosciences, Inc|Total Company Value Theratechnologies Inc. THTX|Company Buyout Price avalotx.com (AVTX)|ELDN - Total Company Value|Agenus, Inc. (AGEN) - Real Price to Acquire Entire Company|CLYM: Enterprise Value|Zura Bio Ltd (ZURA) - Enterprise Value|Real Price to Acquire Entire Company ATYR|ADAG: Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company IMA (ImageneBio Inc)|Aggregate Business Value STTK|Enterprise Value EQ (Equillium)|Value Adjusted for Debt and Cash CNTB|Immunic Inc - Enterprise Value|Total Enterprise Value Atara Biotherapeutics|inflarx.de (IFRX) - Total Company Value|X4 Pharmaceuticals Inc. - Value Adjusted for Debt and Cash|ACET (Adicet Bio Inc.) - Enterprise Value|Enterprise Value Celularity Corp|Total Company Value INmune Bio, Inc. (INMB)|BRNS: Full Business Value|Enterprise Value KZR (Kezar Life Sciences, Inc.)|SAB Biotherapeutics Inc. (SABS) - Total Enterprise Value|AKTX: Real Price to Acquire Entire Company|ENLV - Enterprise Value|QTTB (q32bio.com) - Real Price to Acquire Entire Company|GOVX: Aggregate Business Value|EDSA (Edesa Biotech) - Enterprise Value|iBio Inc (IBIO) - Company Buyout Price|Enterprise Value XTLB|Real Price to Acquire Entire Company boltbio.com BOLT|Total Company Value HCW Biologics HCWB|Company Buyout Price Aptevo Therapeutics, Inc. (APVO)|AIM ImmunoTech Inc. - Enterprise Value|Aditxt (ADTX) - Real Price to Acquire Entire Company|GRI: Enterprise Value|XORTX Corp (XRTX) - Enterprise Value|Total Company Value Vyome Holdings Inc|REVB: Value Adjusted for Debt and Cash|Total Company Value Indaptus Therapeutics, Inc. (INDP)|Real Price to Acquire Entire Company Scinai Immunotherapeutics Ltd SCNI|Total Company Value CalciMedica CALI|AFMD (Affimed NV) - Full Business Value|Allakos Therapeutics - Enterprise Value|Value Adjusted for Debt and Cash HOOK (HOOKIPA Pharma Inc.)|IGMS: Enterprise Value|iTeos Therapeutics Inc (ITOS) - Enterprise Value|Total Company Value Ocean Bio|TCBP: Value Adjusted for Debt and Cash|Total Company Value Third Harmonic Bio (THRD)